Mon, May 18, 2026
Global Edition
VENDETANEWS
May 14, 2026
The FDA has approved early access to daraxonrasib, a promising drug for metastatic pancreatic cancer. Patients with limited treatment options may now qualify for the experimental therapy under a special program, offering new hope in a field with grim survival rates.